<qa>  What is the STUDY OF RO5083945 IN COMBINATION WITH FA STUDY OF RO5083945 IN COMBINATION WITH FOLFIRI VERSUS FOLFIRI PLUS CETUXIMAB OR FOLFIRI ALONE AS SECOND LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER: 